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In the CNS, NPY has been implicated in obesity and feeding, endocrine function and metabolism.
Potent and selective rNPY antagonists will be able to probe the merits of this approach for the
treatment of obesity. We report the synthesis and preliminary evaluation of some hydrazide deriva-
tives as antagonists of rNPY.
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ARTIGO
INTRODUCTION
The Neuropeptide Y (NPY) is a peptide of 36 amino acids,
similar to the peptide YY (PYY) and to the pancreatic
polypeptides (PP)1. At first, separated from the pig brain, the
NPY is well-distributed in the mammals at the level of the cen-
tral and peripheric nervous system. This neurotransmitter is
present in strong concentrations in the nervous fiber of the brain,
but equally as strong in the heart, the sympathetic glands, the
blood vessels and the gastrointestinal tract. It is responsable for
diverse phyisiological effects that exert themselves by way of
specific receptors (Y). These Y receptors form a heterogeneous
group and six subtypes have been identified up to now: Y1 to
Y62. The NPY is involved in the control of appetite, strongly
stimulating the intake of food, or performing a regulatory role
on the HPA (hypothalamic-pituitary-adrenal) axis3. It also
presents anxiolytic and sedative properties that induce an
increase in the blood pressure and affects the circadian rhythm4.
The search for agonists and antagonists of NPY could yield
compounds which could be used in the treatment of pathologies
related to food behavior or energy equilibrium disorders, such
as diabetes, obesity, bulimia and anorexia. Also in the treatment
of arterial hypertension, anxiety, depressions, epilepsia and
sleeping disorders.
The orexigenic effects of NPY could be mediated by it re-
ceptor NPY1 subtype5, which makes it possible to consider that
is involved in the stimulating effect of the appetite of the
neuropeptide Y. Recently, ligands of this receptor have been
described. The first compound of nonpeptide structure with
potent antagonist activity of the receptor NPY1, is BIBP 3226
(Fig.1), which was designed using the region C-terminal of the
NPY6. Recent studies appear to confirm an important implication
of the receptor NPY5 subtype in the control of food ingestion7.
The first Y5-selective antagonists appeared in the patent
literature in mid-19978. These compounds have something in
common: an amino acid, phenylalanine (SR 120819A) and
arginine (BIBP 3226) respectively, in the center part of the
molecule. Also, the amino and carboxyl groups from the amino
acid remain funtionalized in the form of amide. Likewise, the
first selective NPY5 antagonists are appearing. One such
example is JCF 104 (2-(naphtalen-1-yl)-3-phenylpropane-1,2-
diamine)9 (Fig. 1), which carries a rest of 2-amino-3-
phenylpropanamine, closely related to the aforementioned
systems. Our objective is to search for new compounds that are
non-peptidic selective antagonists of the Y5 receptor subtype.
This line of research implies the presence of a phenylalanine
and/or methyltyrosine rest in the central part of a molecule in
which the carboxyl and amine groups of the amino acid are
funtionalized as amide and carbamate respectively (Fig. 2).
Figure 1. Antagonists of the NPY receptors.
Figure 2. General structure for the synthetized compounds.
In this work, the first experimental results are offered. All
the synthetized compounds were evaluated for their antagonist
action of NPY receptors. Their action was evaluated on the
NPY Y1, Y2, Y5 subtype receptors.
CHEMISTRY
Chemicals, methods and apparatus
General laboratory chemicals were purchased from Merck,
Sigma, Janssen, and Scharlau. L-phenylalanine, L-
methyltyrosine, HOBT and EDC was purchased from Fluka.
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All the new compounds were characterized by elemental
analysis, IR and 1H NMR. The IR spectra are recorded on a
Perkin-Elmer FT 681 using KBr pellets. The 1H NMR spectra
are obtained on a Bruker Model AC-200E (200 MHz) with
Me4Si as the internal standard, and at a concentration of
approximately 0.1 g/mL. The mass spectra were obtained on a
Hewlett-Packard HP-5890 (GC/HPLC/DIP) instrument. All
spectra were consistent with assigned structures. Thin layer
chromatography was performed on aluminum sheets precoated
with silica gel (HF 254, Merck). The developed chromatograms
were viewed under UV light or iodine revelation. Melting
points were determined on a Mettler FP82 hot stage apparatus
equipped with a FP800/FP80 processor and an Olympus 8091
microscope provided with a video system and were uncorrected.
Elemental analyses of vaccuum-dried samples were obtained
on a Carlo Erba 1106 elemental analyzer (over P2O5 at 1-2
mmHg, 24 h at 60-80oC). Results are within 0.4% of theoretical
values unless otherwise indicated.
Synthesis of the compounds
General procedure for the preparation of 3-H and 3-(4-
methoxyphenyl)propionic acid derivatives. a-b
The appropiate amino acid was dissolved in NaOH 4 M. The
solution was cooled to 0oC in an ice bath. A solution of the
benzyl chloroformate (equimolar amount) in dry CH2Cl2 and
NaOH 4 M were added alternately and portionwise, with
stirring and cooling, during 30 minutes. The mixture was
allowed to warm with intermitent shaking for 1 h. The mixture
was extracted with ethyl ether (2_15 mL). The aqueous layer
was acidified with diluted HCl (1:1) to pH 2. The solid was
filtered and washed with ethyl ether (3x10 mL) in order to
obtain the product as a solid.
(S)-2-Benzyloxycarbonylamino-3-phenylpropanoic acid (a)
From L-Phe (13.20 g, 80.00 mmol) and benzyl chloroformate
(11.25 g, 80.00 mmol). A white solid (20.87 g, 87%) mp 84.9-
85.4: IR (KBr, cm-1) 3329 (s, N-H), 3033 (m, aromatic C-H),
2942 (m, aliphatic C-H), 1696 (vs, carbamate and carboxylic
acid C=O), 748 and 697 (m, aromatic monosubstitution); 1H-
NMR (CDCl3, δ) 2.74-3.10 (d, d, d, d, 2H, CH2-CH, J=5.5,
5.3, 6.2, 6.4 Hz), 4.06-4.17 (dd, 1H, CH, J=6.0/13.8 Hz), 4.93
(s, 2H, CH2-O), 6.42 (d, 1H, NH, J=7.7 Hz), 7.05-7.35 (m,
10H, C6H5-CH2-CH and C6H5-CH2-O), 10.18 (ws, 1H, OH);
MS m/z 107.05 (10.56), 91.05 (100), 76.95 (12.00); Anal.
(C17H17NO4) C, H, N.
(S)-2-Benzyloxycarbonylamino-3-(4-methoxyphenyl)propanoic
acid (b)
From O-Methyl-L-Tyr (0.50 g, 2.50 mmol) and benzyl
chloroformate (0.36 mL, 2.56 mmol). A white solid (0.65 g,
77%) mp 111.1-113.4: IR (KBr, cm-1) 3305 (s, N-H), 3033
(m, aromatic C-H), 2956 (m, aliphatic C-H), 1696 (vs,
carbamate and carboxylic acid C=O), 746 and 695 (aromatic
monosubstitution); 1H-NMR (CDCl3, δ) 3.01-3.22 (d, t, d,
2H, CH2-CH, J=5.9, 6.0, 5.5 Hz), 3.78 (s, 3H, OCH3), 4.62-
4.71 (dd, 1H, CH, J=5.9/13.5 Hz), 5.11 (s, 2H, CH2-O), 5.21
(d, 1H, NH, J=8.1 Hz), 6.82 (d, 2H, H2 and H6 of C6H4-
OCH3, J=8.5 Hz), 7.07 (d, 2H, H3 and H5 of C6H4-OCH3,
J=8.5 Hz), 7.35 (s, 5H, C6H5-CH2); MS m/z 329.05 (1.50,
M+·), 121.15 (100), 91.05 (12.09), 77.05 (15.22); Anal.
(C18H19NO5) C, H, N.
General procedure for the preparation of final compounds (1-13)
A mixture of the appropiate propanoic acid derivative and HOBT
in dry CH2Cl2 at 0oC, under N2, was treated with EDC. After 1h
at 0oC, a solution of the appropiate hydrazide or hydrazine, in
dry CH2Cl2 was added (equimolar amount of HOBT, EDC, and
hydrazide or hydrazine was used).The reaction was stirred at
0oC for 1 h and then at room temperature for 24 h. The solvent
was evaporated. The residue was redissolved in ethyl acetate or
CH2Cl2 and washed with water (3x20 mL). The organic phase
was dried over Na2SO4 and evaporated under reduced pressure.
The obtained residue was washed with ethyl ether in order to
obtain the product as a solid.
(S)-2-Benzyloxycarbonylamino-3-phenyl-N’-phenylpropiono-
hydrazide (1)
From (a) (1.00 g, 3.34 mmol), HOBT (0.58 g, 3.81 mmol),
EDC (0.73 g, 3.81 mmol) and phenylhydrazine (0.37 mL, 3.81
mmol). A beige solid (0.53 g, 38%) mp 175.0-177.1: IR (KBr,
cm-1) 3297 and 3244 (m, N-H), 3032 (w, aromatic C-H), 2920
(w, aliphatic C-H), 1688 (s, carbamate C=O), 1656 (s, hydra-
zide C=O), 746 and 696 (m, aromatic monosubstitution); 1H-
NMR (CDCl3, δ) 3.07 (d, 2H, CH2-CH, J=7.3 Hz), 4.45-4.60
(dd, 1H, CH, J=7.4/15.1 Hz), 5.06 (s, 2H, Ph-CH2-O), 5.49 (d,
1H, NH-CH, J=8.5 Hz), 5.97 (d, 1H, NH-NH-Ph, J=3.6 Hz),
6.50 (d, 2H, H2 and H6 of C6H5-NH, J=7.9 Hz), 6.85 (t, 1H,
H4 of C6H5-NH, J=7.3 Hz), 7.07-7.35 (m, 12H, C6H5-CH2-O,
C6H5-CH2-CH and H3 and H5 of C6H5-NH), 8.01 (ws, 1H,
CO-NH-NH); MS m/z 389.20 (2.90, M+·), 107.15 (51.51), 91.05
(100); Anal. (C23H23N3O3) C, H, N.
(S)- N’-Benzoyl-2-benzyloxycarbonylamino-3-phenylpropiono-
hydrazide(2)
From (a) (1.00 g, 3.34 mmol), HOBT (0.56 g, 3.68 mmol),
EDC (0.71 g, 3.68 mmol) and phenylhydrazide (0.50 g, 3.68
mmol). A beige solid (0.20 g, 14%) mp 172.2-174.5: IR (KBr,
cm-1) 3285 and 3205 (m, N-H), 3030 (w, aromatic C-H), 1699
(s, carbamate C=O), 1610 (s, hydrazide C=O), 744 and 696
(m, aromatic monosubstitution); 1H-NMR (CDCl3, δ) 2.97-3.24
(d, d, d, d, 2H, CH2-CH, J=8.3, 8.2, 5.9, 6.1 Hz), 4.87-5.06
(m, 3H, CH and CH2-O), 5.98 (ws, 1H, NH-CH), 7.09-7.38
(m, 12H, C6H5-CH2-O, C6H5-CH2-CH and H3 and H5 of C6H5-
CO), 7.48 (t, 1H, H4 of C6H5-CO, J=7.2 Hz), 7.78 (d, 2H, H2
and H6 of C6H5-CO, J=7.8 Hz), 9.52 (ws, 1H, CH-CO-NH-
NH-CO), 9.96 (ws, 1H, CO-NH-NH-CO-Ph); MS m/z 282.15
(14.37), 254.15 (3.91), 105.00 (54.12), 91.05 (100); Anal.
(C24H23N3O4) C, H, N.
(S)-2-Benzyloxycarbonylamino-N’-(2-indolylcarbonyl)-3-
phenylpropionohydrazide (3)
From (a) (0.20 g, 0.67 mmol), HOBT (0.12 g, 0.76 mmol), EDC
(0.14 g, 0.76 mmol) and indol-2-hydrazide (0.14 g, 0.76 mmol).
A beige solid (0.15 g, 49%) mp 176.3-177.5: IR (KBr, cm-1)
3412 (vs, N-H), 3031 (w, aromatic C-H), 2953 (w, aliphatic C-
H), 1697 (vs, carbamate C=O), 1666 (vs, hydrazide C=O), 745
and 697 (vs, aromatic monosubstitution); 1H-NMR (DMSO-d6,
δ) 2.90 (t, 1H, CHAHB-CH, J=11.2 Hz), 3.20 (d, 1H, CHAHB-
CH, J=11.8 Hz), 4.30-4.60 (m, 1H, CH), 4.98 (s, 2H, CH2-O),
6.95-7.55 (m, 13H, C6H5-CH2-O, C6H5-CH2-CH, H3, H5 and H6
of indol-CO), 7.55-7.80 (m, 2H, H4 and H7 of indol-CO), 10.36
(s, 1H, CH-CO-NH-NH-CO), 10.56 (s, 1H, CO-NH-NH-CO-Ph),
11.77 (s, 1H, NH of indole); MS m/z 348.00 (5.41), 143.95
(42.20), 90.95(100); Anal. (C26H24N4O4) C, H, N.
(S)-2-Benzyloxycarbonylamino-3-phenyl-N’-(3-pyridylcarbonyl)
propionohydrazide(4)
A mixture of (a) (0.50 g, 1.67 mmol), HOBT (0.28 g, 1.84
mmol), EDC (0.35 g, 1.84 mmol) and pyridyl-3-hydrazide (0.25
g, 1.84 mmol). A withe solid (0.16 g, 22%) mp 174.0-176.0:
IR (KBr, cm-1) 3419 (s, OH), 3284 (s, NH), 3028 (w, aromatic
C-H), 1691 (s, carbamate C=O), 1659 (s, hydrazide C=O), 745
and 697 (s, aromatic monosubstitution); 1H-NMR (DMSO-d6, δ)
2.84 (t, 1H, CHAHB-CH, J=12.3 Hz), 3.13 (d, 1H, CHAHB-CH,
J=11.9 Hz), 4.31-4.52 (m, 1H, CH), 4.95 (s, 2H, CH2-O), 7.12-
7.44 (m, 10H, C6H5-CH2-CH and C6H5-CH2-O), 7.53-7.59 (m,
1H, H5 of pyridyl-CO), 7.71 (d, 1H, H6 of pyridyl-CO, J=8.6
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Hz), 8.25 (d, 1H, NH-CH, J=7.9 Hz), 8.77 (d, 1H, H4 of
pyridyl-CO, J=3.8 Hz), 9.06 (s, 1H, H2 of pyridyl-CO), 10.39
(s, 1H, CH-CO-NH-NH-CO), 10.72 (s, 1H, CO-NH-NH-CO-
pyridine); MS m/z 418.05 (7.39, M+·), 254.15 (9.12), 91.00
(100); Anal. (C23H22N4O4) C, H, N.
(S)-2-Benzyloxycarbonylamino-N’-(3-indolylacethyl)-3-phenyl-
propionohydrazide (5)
From (a) (0.40 g, 1.34 mmol), HOBT (0.23 g, 1.47 mmol),
EDC (0.28 g, 1.47 mmol) and 3-indolylacetohydrazide (0.28 g,
1.47 mmol). A white solid (0.39 g, 57%) mp 156.7-158.5: IR
(KBr, cm-1) 3279 and 3230 (vs, N-H), 3055 (m, aromatic C-
H), 2920 (w, aliphatic C-H), 1697 (s, carbamate C=O), 1667
and 1608 (vs, hydrazide C=O), 747 and 697 (s, aromatic mo-
nosubstitution); 1H-NMR (DMSO-d6, δ) 2.80 (t, 1H, CHAHB-
CH, J=12.2 Hz), 3.05 (d, 1H, CHAHB-CH, J=12.5 Hz), 3.93 (s,
2H, CO-CH2-indole), 4.31-4.52 (m, 1H, CH), 4.95 (s, 2H, CH2-
O), 6.95-7.20 (m, 3H, H2, H5 and H6 of indolyl-CH2), 7.20-
7.45 (m, 10H, C6H5-CH2-CH and C6H5-CH2-O), 7.50-7.70 (m,
2H, H4 and H7 of indolyl-CH2), 10.41 (s, 2H, CO-NH-NH-
CO), 11.17 (s, 1H, NH of indolyl-CH2); MS m/z 392.05
(11.81), 157.15 (86.51), 130.15 (100), 108.15 (48.18); Anal.
(C27H26N4O4) C, H, N.
(S)- 2-Benzyloxycarbonylamino-3-phenyl-N-(3-pyrazolyl)pro-
pionamide (6)
From (a) (0.50 g, 1.67 mmol), HOBT (0.28 g, 1.84 mmol),
EDC (0.35 g, 1.84 mmol) and 3-aminopyrazole (0.15 g, 1.84
mmol). A white solid (0.23 g, 34%) mp 113.3-114.9: IR (KBr,
cm-1) 3268 (vs, N-H), 3032 (s, aromatic C-H), 2953 (s, aliphatic
C-H), 1713 (vs, carbamate C=O), 1674 (vs, amide C=O), 738
and 697 (s, aromatic monosubstitution); 1H-NMR (CDCl3, δ)
3.05-3.28 (m, 2H, CH2-CH), 4.79-4.93 (m, 1H, CH), 5.06 (dd,
2H, CH2-O, J=12.4/28.0 Hz), 6.61 (d, 1H, NH-CH, J=9.5 Hz),
6.84 (s, 1H, H4 of pyrazolyl-NH), 7.15-7.36 (m, 11H, H5 of
pyrazolyl-NH, C6H5-CH2-CH and C6H5-CH2-O), 11.53 (ws,
1H, CH-CO-NH), 11.72 (ws, 1H, NH of pyrazolyl-NH); MS
m/z 364.05 (0.75, M+·), 256.15 (51.31), 108.00 (26.49), 91.00
(100); Anal. (C20H20N4O3·1_H2O) C, H, N.
(S)-2-Benzyloxycarbonylamino-3-(4-methoxyphenyl)-N’-phenyl-
propionohydrazide (7)
From (b) (0.65 g, 1.98 mmol), HOBT (0.33 g, 2.18 mmol),
EDC (0.42 g, 2.18 mmol) and phenylhydrazine (0.20 mL, 2.18
mmol). A beige solid (0.62 g, 75%) mp 183.0-185.0: IR (KBr,
cm-1) 3299 and 3241 (m, N-H), 3038 (w, aromatic C-H), 2963
(w, aliphatic C-H), 1688 (s, carbamate C=O), 1657 (s, amide
C=O), 739 and 694 (m, aromatic monosubstitution); 1H-NMR
(CDCl3, δ) 2.95-3.10 (m, 2H, CH2-CH), 3.77 (s, 3H, OCH3),
4.46-4.50 (m, 1H, CH), 5.06 (s, 2H, CH2-O), 5.45 (d, 1H, NH-
CH, J=7.5 Hz), 5.98 (d, 1H, NH-NH-Ph, J=3.2 Hz), 6.51 (d,
2H, H2 and H6 of C6H5-NH, J=7.8 Hz), 6.77-6.88 (m, 3H, H4
of C6H5-NH and H2 and H6 of C6H4-OCH3), 6.99-7.11 (m, 4H,
H3 and H5 of C6H5-NH and H3 and H5 of C6H4-OCH3), 7.25
(s, 5H, C6H5-CH2), 7.94 (ws, CH-CO-NH-NH); MS m/z 419.20
(11.70, M+·), 150.15 (29.57), 121.15 (100), 91.05 (74.84); Anal.
(C24H25N3O4) C, H, N.
(S)-N’-Benzoyl-2-benzyloxycarbonylamino-3-(4-methoxyphenyl)
propionohydrazide (8)
From (b) (0.65 g, 1.98 mmol), HOBT (0.33 g, 2.18 mmol), EDC
(0.42 g, 2.18 mmol) and phenylhydrazide (0.30 g, 2.18 mmol).
A beige solid (0.36 g, 41%) mp 208.0-209.2: IR (KBr, cm-1)
3280 (s, N-H), 3033 (w, aromatic C-H), 2925 (w, aliphatic C-
H), 1689 (vs, carbamate C=O), 1655 (vs, hydrazide C=O), 824
(m, aromatic p-disubstitution), 745 and 695 (m, aromatic mono-
substitution); 1H-NMR (CDCl3, δ) 2.90-3.12 (m, 2H, CH2-CH),
3.68 (s, 3H, OCH3), 4.50-4.60 (m, 1H, CH), 4.91-5.06 (dd, 2H,
CH2-O, J=12.3/18.8 Hz), 5.53 (ws, 1H, NH-CH), 6.71 (d, 2H,
H3 and H5 of C6H4-OCH3, J=8.5 Hz), 7.04 (d, 2H, H2 and H6 de
C6H4-OCH3, J=8.4 Hz), 7.10-7.25 (m, 5H, C6H5-CH2-O), 7.34
(t, 2H, H3 and H5 of C6H5-CO, J=7.1 Hz), 7.46 (t, 1H, H4 of
C6H5-CO, J=7.3 Hz), 7.73 (d, 2H, H2 and H6 of C6H5-CO, J=7.5
Hz), 8.90-9.30 (ws, 2H, CO-NH-NH-CO); MS m/z 339.05
(4.01), 150.15 (1.69), 121.15 (100), 115.00 (40.58), 91.05
(63.37); Anal. (C25H25N3O3) C, H, N.
(S)-2-Benzyloxycarbonylamino-N’-(2-indolylcarbonyl)-3-(4-
methoxyphenyl)propionohydrazide (9)
From (b) (0.30 g, 0.91 mmol), HOBT (0.16 g, 1.04 mmol),
EDC (0.20 g, 1.04 mmol) and indol-2-hydrazide (0.19 g, 1.04
mmol). A beige solid (0.20 g, 48%) mp 185.5-186.5: IR (KBr,
cm-1) 3359 (vs, N-H), 3038 (w, aromatic C-H), 2963 (w,
aliphatic C-H), 1707 (vs, carbamate C=O), 1654 and 1606
(vs, hydrazide C=O), 822 (s, aromatic p-disubstitution), 743
(vs, aromatic monosubstitution); 1H-NMR (DMSO-d6, δ) 2.81
(t, 1H, CHAHB-CH, J=12.2 Hz), 3.11 (d, 1H CHAHB-CH,
J=13.7 Hz), 3.74 (s, 3H, OCH3), 4.38 (ws, 1H, CH), 4.97 (s,
2H, CH2-O), 6.87 (d, 2H, H3 and H5 of C6H4-OCH3, J=8.2
Hz), 7.07 (t, 1H, H5 of indol-CO, J=7.2 Hz), 7.10-7.40 (m,
9H, C6H5-CH2, H2 and H6 of C6H4-OCH3 and H6 and H3 of
indol-CO), 7.47 (d, 1H, H4 of indol-CO, J=8.0 Hz), 7.66 (d,
1H, H7 of indol-CO, J=8.4 Hz), 7.98 (d, 1H, NH-CH, J=8.3
Hz), 10.31 (s, 1H, CH-CO-NH-NH-CO), 10.52 (s, 1H, CO-
NH-NH-CO-indole), 11.74 (s, 1H, NH of indol-CO); MS m/
z 335.15 (7.99), 144.05 (55.08), 121.05 (100); Anal.
(C27H26N4O5) C, H, N.
(S)-2-Benzyloxycarbonylamino-3-(4-methoxyphenyl)-N’-(3-
pyridylcarbonyl)propionohydrazide (10)
From (b) (0.30 g, 0.91 mmol), HOBT (0.15 g, 0.99 mmol),
EDC (0.19 g, 0.99 mmol) and pyridyl-3-hydrazide (0.14 g, 0.99
mmol). A white solid (0.25 g, 61%) mp 184.0-186.0: IR (KBr,
cm-1) 3279 (s, N-H), 3033 (w, aromatic C-H), 2958 (w,
aliphatic C-H), 1691 (s, carbamate C=O), 1660 (s, hydrazide
C=O), 813 (w, aromatic p-disusbtitution), 751 and 704 (m,
aromatic monosubstitution); 1H-NMR (CDCl3, δ) 2.93-3.16 (m,
2H, CH2-CH), 3.72 (s, 3H, OCH3), 4.55-4.69 (m, 1H, CH),
4.95-5.09 (dd, 2H, CH2-O, J=12.3/17.3 Hz), 5.66 (ws, 1H, NH-
CH), 6.76 (d, 2H, H3 and H5 of C6H4-OCH3, J=8.4 Hz), 7.08
(d, 2H, H2 and H6 of C6H4-OCH3, J=8.2 Hz), 7.20-7.36 (m,
6H, C6H5-CH2 and H5 of pyridyl-CO), 8.07 (d, 1H, H6 of
pyridyl-CO, J=7.9 Hz), 8.70 (d, 1H, H4 of pyridyl-CO, J=4.8
Hz), 9.01 (s, 1H, H2 of pyridyl-CO), 9.37 (ws, 2H, CH-CO-
NH-NH-CO-pyridine); MS m/z 297.15 (6.82), 121.05 (100),
91.15 (49.17); Anal. (C24H24N4O5) C, H, N.
(S)-2-Benzyloxycarbonylamino-3-(4-methoxyphenyl)-N’-
phenylsulphonylpropionohydrazide (11)
From (b) (0.30 g, 0.91 mmol), HOBT (0.15 g, 0.99 mmol),
EDC (0.19 g, 0.99 mmol) and benzenesulfonyl hydrazide (0.17
g, 0.99 mmol). A beige solid (0.17 g, 38%) mp 167.0-169.0:
IR (KBr, cm-1) 3303 (s, N-H), 3063 (w, aromatic C-H), 2962
(w, aliphatic C-H), 1691 (s, carbamate C=O), 1653 (s, hydra-
zide C=O), 1360 and 1173 (s, SO2), 834 (m, aromatic p-
disubstitution), 734 and 689 (m, aromatic monosubstitution);
1H-NMR (CDCl3, δ) 2.56-2.70 (m, 2H, CH2-CH), 3.69 (s, 3H,
OCH3), 4.19-4.27 (m, 1H, CH), 5.00 (s, 2H, CH2-O), 6.69 (d,
2H, H3 and H5 of C6H4-OCH3, J=8.5 Hz), 6.86 (d, 2H, H2 and
H6 of C6H4-OCH3, J=8.5 Hz), 7.19-7.53 (m, 9H, C6H5-CH2
and H2, H3, H5 and H6 of C6H5-SO2), 7.79 (d, 1H, H4 of C6H5-
SO2, J=7.4 Hz), 9.05 (ws, 2H, CO-NH-NH-SO2); MS m/z
332.15 (7.19), 284.20 (1.36), 121.05 (100), 91.15 (94.19); Anal.
(C24H25N3SO6) C, H, N.
(S)-2-Benzyloxycarbonylamino-N’-(3-indolylacethyl)-3-(4-
methoxyphenyl)propionohydrazide (12)
From (b) (0.57 g, 1.76 mmol), HOBT (0.30 g, 1.94 mmol),
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EDC (0.37 g, 1.94 mmol) and 3-indolylacetohydrazide (0.37 g,
1.94 mmol). A beige solid (0.51 g, 53%) mp 194.0-195.5: IR
(KBr, cm-1) 3410 and 3272 (vs, N-H), 3034 (s, aromatic C-
H), 2949 (m, aliphatic C-H), 1703 (vs, carbamate C=O), 1602
(vs, hydrazide C=O), 824 (s, aromatic p-disubstitution), 735
and 698 (vs, aromatic monosubstitution); 1H-NMR (DMSO-
d6, δ) 2.73 (t, 1H, CHAHB-CH, J=12.0 Hz), 2.98 (d, 1H
CHAHB-CH, J=12.3 Hz), 3.61 (s, 2H, CH2-indole), 3.71 (s,
3H, OCH3), 4.30 (ws, 1H, CH), 4.95 (s, 2H, C6H5-CH2-O),
6.84 (d, 2H, H3 and H5 of C6H4-OCH3, J=7.3 Hz), 6.90-7.40
(ws, 11H, C6H5-CH2-O, H2 and H6 of C6H4-OCH3, H2, H5
and H6 of indolyl-CH2 and NH-CH), 7.55-7.75 (m, 2H, H4
and H7 of indolyl-CH2), 10.17 (s, 2H, CO-NH-NH-CO), 10.92
(s, 1H, NH of indolyl-CH2); MS m/z 500.20 (2.42, M+·),
392.05 (4.80), 157.15 (100), 130.15 (77.01), 108.15 (68.11);
Anal. (C28H28N4O5) C, H, N.
(S)-2-Benzyloxycarbonylamino-3-(4-methoxyphenyl)-N-(3-
pyrazolyl)propionamide (13)
From (b) (0.50 g, 1.52 mmol), HOBT (0.26 g, 1.67 mmol),
EDC (0.32 g, 1.67 mmol) and 3-aminopyrazole (0.14 g, 1.67
mmol). A white solid (0.28 g, 39%) mp 167.7-169.2: IR (KBr,
cm-1) 3268 (vs, N-H), 3032 (s, aromatic C-H), 2953 (s,
aliphatic C-H), 1713 (vs, carbamate C=O), 1674 (vs, amide
C=O), 813 (m, aromatic p-disubstitution), 738 and 697 (s,
aromatic monosubstitution); 1H-NMR (CDCl3, δ) 2.90-3.20
(m, 2H, CH2-CH), 3.69 (s, 3H, OCH3), 4.65-4.85 (m, 1H,
CH), 4.90-5.20 (m, 2H, C6H5-CH2), 6.63-6.81 (m, 4H, H4 of
pyrazolyl-NH, H3 and H5 of C6H4-OCH3 and NH-CH), 7.06
(d, 2H, H2 and H6 of C6H4-OCH3, J=7.8 Hz), 7.15-7.35 (m,
6H, H5 of pyrazolyl-NH and C6H5-CH2), 11.50 (ws, 1H, CH-
CO-NH), 11.65 (ws, 1H, NH of pyrazolyl-NH); MS m/z
286.15 (16.41), 121.15 (100), 108.15 (49.21); Anal.




Binding of iodinated peptide YY (NEN) was carried out as
described by Serradeil-Le Gal10 and modified as follows:
incubations were performed at 30oC for 90 min. with various
competitor concentrations in Buffer A (Herpes/NaOH 20 mM,
MgSO4 0.81 mM, KH2PO4 220 mM, CaCl2 1.26 µM, MgSO4
0.81 mM and bovine serum albumin 0.1%) with SK-N-MC cell
membranes (50 µg of protein/mL of assay) in a total volume of
500 µl. Non-specific binding was determined in the presence of
1 µM NPY. The reaction was then stopped by filtration, the
filters (GF/B, Whatman, pre-coated in 0.3% PEI) were
extensively washed with buffer A, and counted in a gamma
counter (Packard).
Y2 binding assay
Binding of iodinated peptide YY was conducted as descri-
bed by Fuhlendorff et al.11 on membrane prepared from KAN-
TS cells.
Y5 binding assay
Binding of iodinated peptide YY (NEN) was carried out as
described by Hu et al.12. In brief, COS cells transfected with the
human Y5 NPY receptor were lysed and the membranes prepared
by differential centrifugation. These membranes contained about
2 pmol per mg of protein of this receptor. Incubations were
performed in 500 µl comprising, 20 pM final of [125I]PYY in 50
µl. 400 µl of membrane suspension (0.15 mg/mL) and competitor
dilutions in 50 µl, at 30oC for 2 h. The reaction was stopped by
filtration through GF/C filters (Whatman).
Note: Given the nature of the experiment the obtained
values are within an acceptable variability range for this type
of experiments, and therefore the standard errors are not
included in the report.
RESULTS AND DISCUSSION
The carbamate derivatives were obtained as shown in
Scheme 1. Formation of the carbamate is carried out by reaction
of the benzyl chloroformate with the appropriate amino acid
dissolved in a solution of NaOH 4 M. The use of strong basic
mediums is necessary in order to solubilize the amino acids. In
the reactions of the acid group of the amino acid fragment
with amines, hydrazines or hydrazides, the work was carried
out with N-(3-dimethylaminopropyl)-N´-ethylcarbodiimide
hydrochloride (EDC) and 1-hydroxybenzotriazole (HOBT), and
with dichloromethane as the solvent of low dielectric constant.
In each case, the corresponding amides or hydrazides were
obtained. The reaction of the amino group of the amino acid
does not lead to inversion of the configuration, but the reaction
of the carboxyl group may give rise to different percentages of
racemization. In order to avoid this, the reaction has been
carried out with coupling agents that avoid racemization
according to studies carried out by other authors13.
Scheme 1. Synthesis of hydrazide derivatives
The activity of compounds was evaluated by binding assay
conducted as described by Félétou et al.14. Initially, the
antagonist activity of the compounds was evaluated in a
binding assay for Y1, Y2 and Y5 subtypes receptors .
Competetive binding assays were performed using [125I]-PPY
as the radioligand, at concentrations which varied from 15 to
65 pM. The nonspecific fraction is measured in the presence
of a concentration of 1 µM of NPY. The cells are incubated
during a time which varied from 1 to 2 hours depending upon
the classes, and the radioactivity is collected after filtration
with a GF/C filter treated with PEI 0.1%, before being
measured. The data corresponding to the products evaluated
are shown in Table 1.
The results of affinity by the NPY subtype receptors Y1,
Y2, Y5, from which the antagonist activity of the synthetized
molecules has been determined, indicate that the molecules
which were prepared from L-phenylalanine have better behavior
than those prepared from L-methyltirosine. The compound 5
(IC50= 4 µM), which has a heterocyclic system of indole
manifests an important level of activity. These initial results
have convinced us to continue our work in the optimization of
the starting base structure, searching for new highly selective
nonpeptide antagonist of NPY Y5 receptors.
QUÍMICA NOVA, 23(6) (2000) 741
REFERENCES
1. Gehlert, D. R.; Proc. Soc. Exp. Biol. Med. 1998, 218, 7.
2. Blomqvist, A. G.; Herzog, H.; Trends Neurol Sci. 1997,
20, 294.
3. Sahu, A.; Sninsky, C. A.; Kalra, Sp.; Brain Res. 1997,
755, 339.
4. Zimanyi, I. A.; Fathi, Z.; Poindexter, G. S.; Curr. Pharm.
Des. 1998, 4, 349.
5. Kanataki, A.; Ishihara, A.; Asahi, S.; Tanaka, T.; Ozaki,
S.; Ihara, M.; Endocrinology 1996, 137, 3177.
6. Doods, H. N.; Wieland, H. A.; Engel, W.; Regul. Pept.
1996, 65, 71.
7. Leoluca, C, et al.; J. Clin. Invest. 1998, 102, 2136.
8. Rueger, H.; Schmidlin, T.; Rigollier, P.; Yamagichi, Y.;
1997, WO97/20283-A2.
Table 1. Activity of hydrazide derivatives at the Y1, Y2, and Y5 NPY receptors.
Compd. R1 R2 Biological Activity
% Inhib. Y1 % Inhib. Y2b % Inhib. Y2c % Inhib. Y5
1 -H Ph-NH- A>5·10-6 M A>5 10-6 M I A>5·10-6 M
2 -H Ph-CO-NH- I A>5·10-6 M I A>5·10-6 M
3 -H 2-Indolyl-CO-NH- I I I
4 -H 3-Pyridyl-CO-NH- I I 24% 10-5 M
5 -H 3-Indolyl-CH2-CO-NH- 10% 10-5M 36% 10-5 M
6 -H 3-Pyrazolyl- I I I
7 -OCH3 Ph-NH- A>5·10-6 M A>5 10-6 M I I
8 -OCH3 Ph-CO-NH- A>5·10-6 M I I I
9 -OCH3 2-Indolyl-CO-NH- I >10-5 I I
10 -OCH3 3-Pyridyl-CO-NH- I I 22% 10-5 M
11 -OCH3 Ph-SO2-NH- 23% 10-5 M I
12 -OCH3 3-Indolyl-CH2-CO-NH- I I
13 -OCH3 3-Pyrazolyl- I I
I= inactive Y1= rabbit saphenous vein
A= agonist Y2b= dog saphenous vein
Y2c= rat deferens vessel
Y5= rabbit ileum
9. Hong Pheng, L.; Quirion, R.; Iyengar, S.; Fournier, A.;
Regoli, D.; Eur. J. Pharmacol. 1997, 333, R3-R5.
10. Serradeil-Le Gal, C.; Valette, G.; Rouby, P. E.; Pellet,
A.; Oury-Donat, F.; Brossard, G.; Lespy, L.; Marty, E.;
Neliat, G.; de Cointet, P.; Maffrand, J. P.; Le Fur, G.;
FEBS Lett. 1995, 362, 192.
11. Fuhlendorff, J.; Gether, U.; Aakelund, L.; Langeland-Johansen,
N.; Thogersen, H.; Melberg, S.G.; Olsen, U.B.; Thatrup, O.;
Schwartz, T. W.; Proc. Natl. Acad. Sci. 1990, 87, 182.
12. Hu, Y.; Bloomquist, B. T.; Cornfield, L. J.; DeCarr, L.
B.; Flores-Riveros, J.; Friedman, L.; Jiang, P.; Lewis-
Higgins, L.; Sadlowski, Y.; Schaefer, J.;Velazquez, N.;
McCaleb, M. L.; J. Biol. Chem. 1996, 271, 26315.
13. Mizayawa, T.; Otomatsu, T.; Yamada, T.; Kuwata, S.;
Tetrahedron Lett. 1984, 25, 771.
14. Feletou, M et al.; Regulatory Peptides 1998, 75-76, 221
